INTRODUCTION
Chronic hepatitis C virus (HCV) infection has reached pandemic proportions, with an estimated 170 million individuals infected worldwide and approximately 70 000-80 000 in Lithuania, which represents an overall prevalence rate of about 2-2.8 % [1] [2] [3] . Although the course of the disease is highly variable, approximately 20-30 % of patients develop cirrhosis -end-stage liver disease, or hepatocellular carcinoma. Fortunately, treatment with current standard of care, peginterferon and ribavirin (double therapy) and implemented in 2011-2014 yrs new generation of direct acting antivirals (using together with peginterferon and/or ribavirin or without), can improve substantially the treatment results, reduce the complications of chronic liver disease and hopefully solve hepatitis C problem [4, 5, 6, 7, 8] .
The 2002 NIH Consensus Development Conference and recent guidelines for double therapy including Lithuanian guidelines recommend that all patients with chronic hepatitis C (CHC) should be considered as potential candidates for this therapy [9] [10] [11] [12] [13] [14] [15] . These agents yield sustained virological response (SVR) rates of about 40-45 % in patients with genotype 1 and 75-80 % in patients with genotypes 2 and 3.
However, these data of efficacy are obtained by randomized controlled trials performed on patients selected using strict inclusion and exclusion criteria, which means that those patients not necessarily represent the HCV population treated in routine clinical practice in terms of disease severity or presence of co-morbidities [16] . In the normal clinical setting a greater variety of patients are being treated. In addition treatment efficacy may also be influenced by the occurrence of adverse events, a problem that may be of great importance in developing countries or in geographical areas with high prevalence of CHC where the majority of patients are treated outside randomized controlled trials [17] . Imperfect patients adherence to combination therapy is common in routine clinical practice and possibly may also diminish effectiveness of the treatment [18] .
Therefore the efficacy of antiviral treatment and predictors of treatment success in "real life" practice may differ from that in clinical trials and remain to be established. The reports on the "true life" results of pegylated interferon and ribavirin in treatment-naive patients are controversial. Re-two groups: naives -non-treated -125 (61,6 %) and experienced -previously unsuccessfully treated -78 (38,4 %) (Fig. 1) .
HCV antibodies were identified with a microparticle enzyme immunoassay (AxSYM hepatitis C virus version 3.0; Abbott Laboratories, 65205 Wiesbaden, Germany), and qualitative and quantitative HCV ribonucleic acid determinations were made by polymerase chain reaction (PCR) (AMPLICOR hepatitis C virus Test, version 2.0 and AMPLICOR hepatitis C virus Monitor Test, version 2.0, respectively; Roche Diagnostics GmbH, D-68298 Mannheim, Germany). HCV genotyping and subtyping were performed via PCR followed by a line probe assay (INNO-Li-PA hepatitis C virus II; Innogenetics, 9052 Gent, Belgium).
The HCV RNA < 600 000 IU/ml was considered as low viremia level and > 600 000 IU/ml -as high. According to Lithuanian guides just qualitative HCV test was performed for naive patients with genotype 2 and 3 [12] [13] [14] . Viral load before and during treatment course for those patients was not required. Routine biochemical parameters -ALT, AST, ALP and γGT activity, tests for evaluation functional liver capacity (bilirubin and albumin concentration, prothrombin index) and immunological parameters for exclusion of autoimmune hepatitis (serum IgA, IgG, IgM-by immunoassay; autoantibodies ANA and AMA -by immunofluorescence) and serological markers of HBV infection (HBsAg, anti HBc, anti HBs, anti HBe -by "Abbott EIA" commercial tests) for exclusion of hepatitis B infection were carried out too.
Ultrasound and Histology Evaluation
All patients underwent ultrasound examination by LO-GIQ500 PRO series (General Electric, Yokogava Medical System, Yokogawa, Japan). Echo-guided liver biopsy was performed in the most patients -197 (97 %) and it was eliminated only because of contraindications. Histological evaluation of biopsy specimens was carried out at the National Center of Pathology (accredited by the Association of American Pathologists in 2000 year). Necroimflammatory activity and histological activity index (HAI) was scored according to Ishak et al. (1995) [22] , while fibrosis (F) -according to METAVIR scoring system (1994) [23] . 
Treatment

Treatment Schedule
PegIFN alfa-2a (Pegasys) was given at a unique dose 180μg to all patients, while PegIFN alfa-2b (PegIntron) dose was adjusted to the patient's body weight -1,5μg/kg weekly in combination with RBV (Copegus or Rebetol). The RBV dose was also adjusted to the body weight: in patients with the weight less than 65 kg, the dose was 800 mg daily, for 66-85 kg patients -1000 mg, for those with a weight 86 kg and equal or more 100 kg -1200 mg daily. Participants being on treatment were examined every month on an outpatient's basis. According to Lithuanian guides (2003-2008 years) , treatment course lasted 24 weeks for naives with genotype 2 and 3 and genotype 1 patients with low viremia ( if HCVRNA in the last ones becomes negative after 4 weeks of therapy); for naive genotype 1 patients with high viremia and all experienced ones, irrespective to genotype, duration of therapy -48 weeks [12] [13] [14] . Treatment had to be withdrawn whenever HCV RNA load after 12 weeks decreased less than 2 log from baseline level or found positive after 24 weeks of therapy.
Assesment of efficacy
The primary measure of efficacy was SVR (sustained virological response), defined as HCV RNA not detectable in serum 24 weeks after the end of therapy. In addition, we evaluate virological response at the end of treatment (EVR) (HCV RNA not detectable at the end of treatment).
Statistical analysis
The statistical analysis was descriptive to reflect the clinical routine as intended by the clinicians. Data are presented as the percentage or the mean ± standard deviation (SD). Univariate and multivariate logistic regression analyses were applied to test independent variables known from the literature to be associated with the response. All variables reaching a P-value of P < 0.1 in the univariate analysis were then tested for significance by multivariate logistic regression analysis. Analysis of variables was performed by Student's ˝t˝ test (SPSS statistical analysis version 17.0 software for Windows). Differences were considered significant if p<0.05. 
RESULTS
Baseline patients characteristics
Both intent-to-treat (ITT) and per protocol (PP) analysis were used. Baseline ITT patients characteristics (203 patients -107 (52,7 %) males and 96 (47,3 %) females) are presented in Table 1 . The group of patients was consisted of naive patients 125 (61,6 %) and experienced ones treated previously with combination of standard IFN or Peg IFN plus ribavirin -78 (38,4 %). Naive patients were younger than experienced ones and females prevailed (58.3 %). Most patients 75,9 % were infected with HCV genotype 1 and no difference in the distribution of genotypes in naive and treated patients was found. Experienced treatment patients were older then naives especially females.
Out of the 203 patients, 24 were withdrawn from the analysis of treatment efficacy and per protocol analysis was made. This group consisted from patients who discontinued treatment (overall n-11), because of side effects (n-8) or were lost during treatment course because of personal reasons (n-3) and those previously unsuccessfully treated patients who treatment duration was not adequate i.e. lasted just 6 months (n-13). PP group contained 179 patients -93 (52 %) males and 86 (48 %) females 115 (64,2 %) were naives and 64 (35,8 %) -treatment experienced. Age ranged from 20 to 77 years with the mean average (± SD) 48,1 ± 13,7 years. 106 (59,2 %) patients were younger and 73 (40,8 %) older than 50 years of age. HCV genotype 1 was found in 132 (73,7 %) , genotype 2 in 10 (5,6 %) and genotype 3 in 37 (20,7 %) of all the patients. Low viral load (< 600 000 IU/ml) was observed in 42 (23,5 %) and high -> 600 000 IU/ml -in 100 (55,9 %) of HCV patients overall. AST, ALT and γGT liver enzymes activity fluctuated in a very wide range: from normal to 10 (ALT), 22 (AST) and 8,5 (γGT) times higher than UNL. Liver biopsy was performed in 175 (97,8 %) patients: 36 (20,1 %) of them had F3 -4 and F 4, and the majority 138 (77,1 %) − F1, F2 and F2-3 fibrosis stages. The mean fibrosis stage (± SD) was 2,56 ± 0,8. The mean (± SD) histological activity index (HAI) -5,2 ± 1,8 scores. Steatosis of different grade was found in 51,4 8 % of biopted patients: steatosis less than 10 % prevailed in patients with genotype 1 and 2 (in 62 % and 75 %, respectively), whereas greater than 10 % -in patients with genotype 3 (in 90 %, p < 0,001). Steatosis was statistically significantly related to HAI (p = 0,037), while the latter correlated directly with fibrosis stage: the higher HAI, the greater stage of fibrosis (p = 0,003). In 68,75 % of patients having HAI > 9 scores higher fibrosis stage (F3 4) was found (p = 0,003) (Fig. 2) . 
Results of Treatment with Pegylated Interferon and Ribavirin
In the ITT analysis the overall rate of sustained virological response (SVR) was 39,4 % (80/203): 28,6 % in genotype 1, 80 % in genotype 2 and 71,8 % in genotype 3 patients. In naive patients it was 47,2 % and in treatment experienced -27 %. The SVR was achieved in 35,1 % (33/94) of naives with genotype 1, in 100 % (7/7) with genotype 2 and in 79,2 % (19/24) with genotype 3. Meanwhile in experienced patients with genotypes 1, 2 and 3 SVR was found in 18,3 %, 33,3 % and 60 %, accordingly.
All treatment results and correlations in this article will be presented as per protocol. (Table 2 and 3) .
The overall ETR was observed in 55,3 % (99/179) patients: in 66,1 % of naive and in 35,9 % of previously treated ones. The overall rate of SVR was 43 %: in 31,1 % of genotype 1 patients, 80 % -genotype 2 and 75,7 % -genotype 3. The SVR occurred in 51,3 % of naive and in 28,1 % of previously treated patients. In naive genotype 1 patients SVR was achieved in 38,8 % cases, genotype 2 -in 100 % and genotype 3 -in 82,6 % SVR rate of experienced patients was significantly lower: in 17 %, 33,3 % and 64,3 % of cases, accordingly (Table 2 ).
In the univariate and multivariate statistical analysis significant relations of SVR and HCV genotype was observed: 68,9 % of patients having genotype 1 were non-responders, whereas 80 % and 75,7 % ones with genotype 2 and 3, respectively, achieved SVR: OR 9.871 (2.013-48.403), p < 0,005 and OR 16.289 (1.954-135.801); p =0.01, respectively) (Table 3 and Fig. 2 ). This relation was statistically significant in both treated patients groups -naive and treatment experienced.
Inverse correlation of SVR rate with the patients age was confirmed by univariate and multivariate analysis: OR 3.896 (1.578-9.616, p = 0.003) and OR 4.48 (1.422-14.112, p < 0,001). (Table 3) . It was especially evident in naive patients, who SVR was significantly higher (twice) in those younger than 50 years of age compared with the older ones. Overall 69.2 % of patients older than 50 did not respond to the treatment (p < 0,001). However no statistically significant correlation of SVR and age was observed in treatment experienced patients (Table 3) .
No significant SVR difference between males and females was found too. Moreover SVR of naive females overall and those with genotype 1 was even lower than in males. However it was not statistically significant. Inverse relation of SVR with the degree of fibrosis was observed in univariate and multivariate statistical analysis: the higher fibrosis stage, the lower SVR rate was achieved (54 % 
DISCUSSION
Peginterferon plus ribavirin combination therapy up to 2011 was the current standard of care in treatment patients with CHC [6, [9] [10] [11] . Three large industry-sponsored, multinational, phase III, randomized-controlled clinical trials (RCTs) have found that combined treatment with pegylated interferon (PEG-IFN) α-2a or α-2b and ribavirin leads to a SVR in 54-63 % of treatment naive CHC patients: about 40-45 % in patients with genotype 1 and 75-80 % in genotypes 2 and 3 [24] [25] [26] . Meanwhile, in those who had failed to respond to prior treatment with interferon alone or in combination with ribavirin and were re-treated with pegylated interferon and ribavirin, the response rate was significantly lower, ranging from 20 to 40 % (28 %) and from 8 to 12 %, accordingly [27] [28] [29] . Pretreatment predictors of the response are useful for advicing patients on their likelihood of an SVR. So far, numerous factors, including host-, virus-and treatment-related elements have been identified as significant predictors of SVR or non SVR [6, [24] [25] [26] [29] [30] [31] . Patients infected with "easy-to-treat" genotypes 2 and 3 respond much better than those with "difficult-to-treat" genotypes 1 and 4. HCV genotype, pretreatment viral load, ethnicity, gender, presence of cirrhosis or advanced fibrosis, obesity, steatosis, insulin resistance, elevated γGT and other are significantly associated with the outcome of Peg-IFN plus RBV combination therapy [32, [34] [35] [36] [37] [38] . Furthermore, those with low pretreatment viral load respond much better than those with high pretreatment viral load. Data on predictors usually comes from RCT and are the basis for the development of clinical guidelines and for decisions regarding patient management.
However RCT results on antiviral treatment outcomes as well as predictors of its efficacy may not reflect the results in routine clinical practice, and studies carried out in 'true life' are needed to confirm these conclusions. In clinical practice we treat 'real patients' and cannot select the best candidates for treatment, as in RCT. Additionally, there is possible that the treatments efficacy given in clinical trials may be affected by greater patient⁄ doctor motivation and⁄or closer supervision than that feasible in routine clinical practice [32, 36] . Moreover efficacy of the treatment may be reduced by the treatment discontinuation because of side-effects which may be higher than in RCT [37] .
Aiming to clarify the treatment outcomes and efficacy of combined therapy with peginterferon and ribavirin in treatment naive and treatment experienced HCV patients, and to evaluate possible predictors of SVR we carried out retrospective analysis of the data obtained in routine clinical practice.
The reports on the "true life" treatment results with pegylated interferon and ribavirin of HCV infected patients are controversial. Some studies showed SVR similar to that obtained during RCT. Danish nationwide cohort study [38] , presented the data obtained in a routine clinical practice and found them comparable to those observed in controlled clinical trials: overall 57.9 % of patients achieved SVR: it was 46.5 % in patients with genotype 1/4 infection and 77.3 % in those with genotype 2/3 infection. Some other authors [39] [40] [41] [42] [43] [44] [45] and community based studies in Germany, Canada, France and Australia [46] [47] [48] [49] [50] [51] reported SVR data comparable with those in RCT too. Conversely, results of other investigators were lower [52, 53] . Retrospective, observational cohort study in US veterans population also found significantly lower SVR rates, than in clinical trials ie 20 %, 52 % and 43 % in genotypes 1, 2 and 3, respectively [19] . The authors concluded that clinicians should not assume that results from registration trials are transferable to their own clinical practice. The lower SVR rate (37.5 %) of patients in "real life" treatment study and low eligibility to therapy at general population level in a highly endemic area was presented by Mariano et al (2009) and in nationwide retrospective treatment study in Hungary [54, 55] . In our study overall sustained virological response in ITT/PP analysis was achieved in 39,4 % /43 % patients: in 47,2 % / 51.3 % of naive and 26.9 % / 28.1 % of treatment experienced patients, respectively. Among naive patients, the SVR was 35,1 % / 38.8 % in genotype 1, 100 % / 100 % -in genotype 2, 79,2 % / 82,6 % -in genotype 3 patients; and in 18,3 % / 17 %, 33,3 % / 33 % and in 60 % / 64,3 % of treatment experienced patients in per ITT/PP analysis, accordingly. Our data of SVR in per protocol analysis did not differ significantly from those in ITT, so further only the results obtained in per PP analysis will be discussed.
Rather low overall SVR of our patients might be explained by the specific features of the treatment experienced patients subgroup which comprised actually 38 % of the overall group, most of them were males (70,3 %), with prevalence of older ones (over 50). Moreover 53,1 % and 34,6 % of them had advanced fibrosis and cirrhosis (F3-4 and F4). There is well known and confirmed by other investigators that above-mentioned patients population usually showed significantly lower SVR rate than naives, more younger ones, females and those without advanced fibrosis or cirrhosis [24-26, 33, 42, 56] .
The treatment results of naive patients in our study correspond with the data of some "real life" studies -German multicenter open label study and Canadian Power program, being slightly lower in genotype 1 and higher in genotype 2 and 3 patients [45, 48] . SVR of naive patients overall and those with genotype 1 were also very similar to the results presented in classical clinical trial carried out by Manns, but higher for patients with genotype 2 and 3 (91,3 % and 82,76 % vs 80 %) [25] . When comparing SVR results of our patients with genotype 1 with the data obtained in other RCT and community based studies carried out in Europe and USA they were slightly lower (38,8 % vs 46 % and 52 %) [24, 26, 48, 50] .
The overall SVR of treatment experienced patients in our study was 43 % and differed significantly depending on genotype: it was very low for genotype 1 patient (17 %), but rather high in those with genotype 3 (64,3 %). Just three previously unsuccessfully treated patients with genotype 2 were treated repeatedly and SVR was achieved in 2 of them. Previous treatment was performed with standard interferon alfa 2b and ribavirin mostly (in 2/3 of patients) or with interferon monotherapy and combination of peginterferon plus ri-bavirin in the other third of patients. Low SVR of treatment experienced genotype 1 patients is in accordance with the data of other investigators [50, [57] [58] [59] [60] and are very similar to the findings obtained in observational French study: they found SVR 39 % in ITT population: 43 % in naive and 31 % in treatment-failure patients, but was lower in comparing with the results of others [61] . HCV genotypes are considered as the strongest baseline predictors for response for dual therapy and our data confirmed that: HCV genotype 1 is the major negative predictor of SVR -"difficult to treat genotype" by univariate and multivariate analysis. Almost 70 % of patients having genotype 1 were non-responders, whereas 80 % and 75,7 % of those with genotype 2 and 3 "easy-totreat" ones, respectively, responded well.
Our results regarding genotypes as the strong predictors of SVR correspond to the data of the majority of other investigators obtained in RCT and in "real life" studies [10, 24, 25, 28, 31, 32, 33, 40, 42, 46, [48] [49] [50] .
The inverse correlation of SVR with the patients age was detected too and confirmed by univariate and multivariate analysis. It was evident in naive patients subgroup especially, where SVR was twice as high in those younger than 50 years compared with the older ones. Overall 69,2% of naive patients over 50 did not respond to the treatment (p < 0,001). Inspite of the same SVR trend in treatment results of experienced patients inverse correlation with the age was weak and statistically not significant.
Our data confirmed that older age increases the risk of primary treatment failure and correspond to the data of other investigators who found inverse relation of age and SVR [24-27, 31-34, 40, 44, 45, 61, 56] .
Majority of RCT and community based studies found that high pretreatment viral load and presence of advanced fibrosis or cirrhosis are strong independent negative predictors of SVR in combined antiviral treatment [15, 24, 25, 40, 44, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] .
Our data also confirmed the advanced fibrosis and cirrhosis as the strong negative predictors of SVR: the higher fibrosis stage the lower SVR rate was achieved SVR of naive and treatment experienced patients with F1-2 was almost twice and seven times higher, accordingly, than in those with advanced fibrosis and cirrhosis (F3 and F4).
Statistically significant correlations with viral load were not found either in naive or in experienced treatment patients. Some differences of SVR between males and females were observed, but statistical analysis did not confirm female gender as significant positive predictor of SVR neither by multivariate nor univariate analysis. Naive females in our study showed even lower SVR than males (60,4 % vs 44,8 %, p < 0001). Possible reason -females were older than males.
There are contradictory data regarding impact of female gender on antiviral treatment outcome. Some investigators found female gender as the positive predictor for SVR in RCT and in "real life condition"studies [9, 24, 25, 56, 63, 64] . The others did not confirm these results [20, 40, 42, 44, 65] , or even found that response to combined treatment and SVR in females 50 years old or older was poorer than in males [66] . Low estrogens level in older women could be responsible for their impaired response to antiviral treatment.
Steatosis of different grade was found in 51,4 8 % of our biopted patients: steatosis less than 10 % prevailed in patients with genotype 1 and 2 , whereas it was greater than 10 % -in patients with genotype 3 (in 90 %, p < 0,001). No correlations of SVR with steatosis and its grade were found neither by univariate nor multivariate analysis.
Several investigators reported that increased γGT activity strongly associates with primary antiviral treatment failure [21, 64, [67] [68] [69] . Weak trend of inverse SVR correlation with γGT activity was found in our study by univariate analysis too [OR 2.242 (0.956-5.259), p-0,063], but it was not confirmed by multivariate analysis.
We also found no correlations of SVR with HAI and ALT activity neither by univariate nor multivariate analysis.
Data regarding those variables are contradictory: some investigators found positive predictivity of ALT activity higher than 3 times UNL and higher HAI scores for SVR [44, 59, 72, 73] , the others did not confirm any correlation of ALT and SVR [70] .
Our data confirmed that antiviral treatment after previous unsuccessful course is strong negative predictor for achieving SVR by univariate and multivariate analysis, accordingly [OR 7.037 (1.970-25.134, p-0,003) and OR 7.370 (1.368-39.713, p-0,002)].
IN CONCLUSION
Results of SVR obtained in our study "on real life" conditions are non unambiguous: SVR of naive patients overall and those with genotype 1 were similar or slightly lower while for patients with genotype 2 and 3 higher than results presented in RCT. The same trend of SVR was observed in treatment experienced patients too: as compared with data of clinical studies SVR was lower in genotype 1 patients, but higher in genotype 3. The strongest negative predictors for SVR were genotype 1, previous unsuccessful course of antiviral treatment, older age (>50yrs), and advanced fibrosis and cirrhosis.
